SI
XLRN

Sofinnova Investments’s Acceleron Pharma XLRN Stock Holding History

Sofinnova Investments’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,589
Closed -$6.81M – 85
2021
Q3 		$6.81M Sell
39,589
-194,049
-83% -$25.4M 0.4% 47
2021
Q2 		$29.3M Buy
233,638
+55,100
+31% +$6.95M 1.69% 14
2021
Q1 		$24.2M Buy
178,538
+141,850
+387% +$18.3M 1.46% 18
2020
Q4 		$4.69M Sell
36,688
-22,858
-38% -$2.68M 0.28% 50
2020
Q3 		$6.7M Sell
59,546
-157,844
-73% -$15.7M 0.5% 37
2020
Q2 		$20.7M Buy
217,390
+52,230
+32% +$5.03M 1.31% 22
2020
Q1 		$14.8M Buy
165,160
+18,128
+12% +$1.41M 1.37% 17
2019
Q4 		$7.8M Sell
147,032
-261,230
-64% -$11.9M 0.56% 36
2019
Q3 		$16.1M Buy
408,262
+167,219
+69% +$7.25M 1.46% 21
2019
Q2 		$9.9M Buy
+241,043
New +$9.98M 0.91% 26

Sofinnova Investments's XLRN Position: Q4 2021 in Review

Sofinnova Investments sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 39,589 shares — an estimated $6.81M sold.

Sofinnova Investments first reported a position in XLRN in Q2 2019 and held it in 10 quarters. The position peaked at $29.3M in Q2 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Sofinnova Investments reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Sofinnova Investments sold 39,589 Acceleron Pharma shares in Q4 2021, an estimated $6.81M.
  • Sofinnova Investments first reported a position in Acceleron Pharma in Q2 2019 and held it in 10 quarters.
  • Sofinnova Investments's Acceleron Pharma position peaked at $29.3M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.